Stay updated with breaking news from Initial Dose Escalation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
![Aimmune Therapeutics, Inc.: Aimmune Therapeutics to Present New Data for PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022 - Vimarsana News](https://vimarsana.com/images/vimarsana-bigimage.jpg)
Analysis to be Presented Showed Peanut Allergy Treatment with PALFORZIA was Associated with Improvements in Health-Related Quality of Life among Patients and Caregivers -Additional Data to be Presented
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU) a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
Posted on 192 Aimmune Therapeutics, a Nestlé Health Science company developing and commercializing treatments for potentially life-threatening food allergies, today announced new clinical data from a pooled analysis of three controlled phase 3 (PALISADE 1, RAMSES, ARTEMIS 3, ARC008, ARC011) trials of PALFORZIA ® [Peanut ( Arachis hypogaea) Allergen Powder-dnfp]. These data will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting held February 26 – March 1, 2021. In patients with p...